[1] NATALIA LECIEJEWSKA . Sex-specific cytotoxicity of ostarine in cardiomyocytes[J]. Molecular and Cellular Endocrinology, 2023, 577: Article 112037. DOI:
10.1016/j.mce.2023.112037.
[2] HARJOT BEDI. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator.[J]. ACG Case Reports Journal, 2021: e00518. DOI:
10.14309/crj.0000000000000518.
[3] PJ R, D H, JC C, et al. Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.[J]. Front Endocrinol (Lausanne), 2020, 11: 556581.
[4] JAMES T. DALTON. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial[J]. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2 3: 153-161. DOI:
10.1007/s13539-011-0034-6.
[5] ADRIAN S DOBS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.[J]. Lancet Oncology, 2013, 14 4: 335-345. DOI:
10.1016/S1470-2045(13)70055-X.
[6] JEFFREY CRAWFORD. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).[J]. Current Oncology Reports, 2016, 18 6: 37. DOI:
10.1007/s11912-016-0522-0.
[7] ALVARO MORALES. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.[J]. Canadian Medical Association journal, 2015, 187 18: 1369-1377. DOI:
10.1503/cmaj.150033.
[8] Watts D. Ostarine Reviews: shocking results & information about MK2866. SECEC. https://secec.org/ostarine-mk2866/. Accessed May 18, 2020.